Clinical Trial Update: Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients [Phase 4]

View source ↗

Summary

Phase 4 trial updating entecavir use for preventing hepatitis B reactivation in patients with inflammatory arthritis undergoing biological agent therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Rheumatoid Arthritis

Drugs mentioned

• ENTECAVIR (ENTECAVIR)

Snippet

Sponsor: Taipei Veterans General Hospital, Taiwan | Conditions: Rheumatoid Arthritis, Hepatitis B Reactivation | Phase 4 | Status: UNKNOWN